Search

everythinglearnresearchcommunity

for

Search:↓

Skin fungal infections are more common in older adults due to factors like obesity, poor circulation, reduced mobility, and weakened immune defenses from certain medications.

Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.

Lichen planopilaris is a rare, chronic condition causing hair loss, mainly in middle-aged women, and early treatment is important to prevent permanent baldness.

In 2002, various skin reactions were reported due to different drugs, including allergies, hair loss, skin lesions, and other skin conditions.

People with Lichen Planopilaris are more likely to have autoimmune diseases, especially Systemic Lupus Erythematosus, and less likely to have diabetes and some other common conditions.

Lichen planopilaris is a chronic, scarring hair loss condition with no definitive cure, requiring accurate diagnosis and treatment to manage symptoms.

Effective treatments for lichen planopilaris are unclear due to inconsistent results and a lack of strong research evidence.

In Italian patients with lupus, the most common skin issue was chronic cutaneous lupus, especially discoid lesions, and nonspecific skin problems occurred in about a third of those with systemic lupus, mainly during active disease.

Some patients receiving pegylated interferon alfa injections developed skin necrosis, requiring treatment adjustments or discontinuation.

Biologic treatments for Crohn's disease and ulcerative colitis can cause skin problems, and doctors should adjust treatment if these occur.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

Antimalarial agents are effective for LPP, and intralesional steroids are effective for FFA.

Most treatments for lichen planopilaris were found to be generally unsatisfactory.

Low-Level Light Therapy significantly reduced inflammation and promoted hair regrowth in patients with Lichen planopilaris.

Beta-blockers can cause rare skin side-effects, which usually improve after stopping the medication.

Most people with systemic lupus erythematosus have skin problems, and skin symptoms are often the first sign of the disease.

Patients with chronic graft-versus-host disease often have skin problems like vitiligo and alopecia areata.

Lichen Planopilaris in teens is rare, often misdiagnosed, and responds well to steroids.

Some COVID-19 patients have different skin problems, which might be the only sign of the virus or related to other health issues.

Foreign-body granuloma may be a marker for late-stage Lichen Planopilaris and should be considered in diagnosis.

Oral zinc and Nd:YAG laser therapy effectively treated primary cicatricial alopecia in five patients.

Most patients with Cutaneous Lupus Erythematosus are young females, and dermatologists play a key role in diagnosis.

Lichen planopilaris can occur with multiple autoimmune diseases.

Celiac disease can cause skin problems that may get better with a gluten-free diet.

People with Lichen planopilaris are more likely to have certain autoimmune and endocrine disorders but less likely to have conditions like allergies and diabetes.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Skin issues can indicate immune system problems.

The conclusion is that certain scalp tissue changes are characteristic of lichen planopilaris, with mucinous perifollicular fibroplasia being a new feature for diagnosis.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

The document concludes that recognizing and treating cutaneous lupus erythematosus early is crucial for managing the skin and potential systemic symptoms.